Clinical data indicates that a high body mass index (BMI) in multiple myeloma patients is associated with more aggressive disease biology and poorer treatment outcomes. This is an independent risk factor, separate from common comorbidities like diabetes or hypertension.

Insulin resistance manifests in non-obvious physical signs long before blood sugar becomes abnormal. These include skin tags, velvety darkened skin on the neck (acanthosis nigricans), and loss of hair on the toes. These are early warning signs of metabolic dysfunction that can be visually identified.

With half its patients from Asia and only 13% from North America, the Destiny Breast 11 trial's results may not be fully generalizable to US patients. Differences in metabolism, healthcare systems, and side effect reporting across regions can impact outcomes, a key consideration when interpreting global trial data.

On-body glucose monitors give oncologists a richer understanding of a patient's glucose control, including 24-hour trends, time-in-range, and an A1c equivalent (GMI). This real-time data is critical for managing hyperglycemia from targeted therapies, offering more insight than periodic fasting tests.

Contrary to popular belief, research shows that individuals with a higher Body Mass Index (BMI) often live longer than those with 'normal' or low BMI. Higher body weight can be protective against conditions like osteoporosis and cancer and can aid faster recovery from heart surgery.

Advanced health tech faces a fundamental problem: a lack of baseline data for what constitutes "optimal" health versus merely "not diseased." We can identify deficiencies but lack robust, ethnically diverse databases defining what "great" health looks like, creating a "North Star" problem for personalization algorithms.

Oncologists typically initiate metformin for drug-induced hyperglycemia but are hesitant to manage more complex regimens. They prefer collaborating with endocrinologists who can navigate different drugs, dosages, and interactions, especially for complex oncology patients where frequent follow-up is needed.

Steroid-induced hyperglycemia is a primary driver of cancer-related high blood sugar. Patients with prediabetes (A1C 5.7-6.4%) are often overlooked but frequently develop hyperglycemia on high-dose dexamethasone, making proactive warnings and dietary guidance crucial for this group.

Leading longevity research relies on datasets like the UK Biobank, which predominantly features wealthy, Western individuals. This creates a critical validation gap, meaning AI-driven biomarkers may be inaccurate or ineffective for entire populations, such as South Asians, hindering equitable healthcare advances.